ClinicalTrials.gg
CompletedNCT04303039Updated Jun 23, 2020

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

A Phase 1 interventional study of ABP-671 in Gout and Food-drug Interaction, sponsored by Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Gout with a site in United States — 12 open to participants now, 16 under way, 3 of them phase 3. Gout · United States.

Enrollment
138th of 149
12 · median 74
Started
2020
with 10 others
Phase 1
32 of 164
none open now
Registered
115th of 164
by date

Among the 164 studies in Gout with a site in United States, this one is the 138th largest by enrollment of the 149 interventional ones that give a count, is one of 11 that started in 2020, is one of 32 in phase 1, and was the 115th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

12 of the 164 studies in Gout with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Gout with a site in United States, or all of them as a file.
02

Study summary

This is a single center, open-label, single-dose, 2-way randomized crossover design in which 12 healthy subjects will be randomized to 1 of 2 treatment sequences (AB or BA). Treatments A and B will consist of single oral dose of tablet formulation (1.0 mg as 1 x 1.0 mg) in the fasted and fed state administered with approximately 240 mL of water. Each period will be separated by a washout interval of 4 days.

03

Conditions studied

  • Gout
  • Food-drug Interaction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 60 years, inclusive
  • Healthy
  • Subjects must have the serum uric acid level at screening ≥ 3.7 mg/dL to ≤ 7.0 mg/dL for males, and ≥ 2.3 mg/dL to ≤ 6.0 mg/dL for females.
  • Subjects must have a (BMI) between 18 and 35 kg/m2 at screening (inclusive).
  • Subjects must have a body weight of 50 kg or higher.
  • Females must be non-pregnant and non-lactating
  • Males must be surgically sterile, abstinent, or if engaged in sexual relations with a female partner of , be using a condom with spermicide
  • Subjects must have a CBC and count within normal range
  • Subjects must have normal blood chemistry
  • Subjects must have a normal urinalysis
  • Subjects meeting inclusion and exclusion criteria must have a renal ultrasound determined to be normal or non-
  • Subjects must have a normal estimated
  • Subjects must have a normal
  • Subjects must be able to comply with the study and follow-up procedures
  • Subjects are able to understand the study procedures and risks involved and must provided signed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Subjects with any history or clinical manifestations of significant metabolic, hematological, pulmonary, including latent tuberculosis, cardiovascular, gastrointestinal including cholecystectomy, neurologic, hepatic, renal, urological, or psychiatric disorders.
  • Subjects with prior history of bariatric surgery, intestinal resection, malabsorption, or celiac disease with an exception of subjects with appendectomy.
  • Subjects who have any history or suspicion of kidney stones or evidence of renal stones or opacification with renal ultrasound prior to dosing on Day -1.
  • Subjects who have any history of gout.
  • Subjects who are positive for (HIV), surface antigen, and/or virus.
  • Subjects who have used prescription drugs, over-the-counter drugs, or herbal remedies within 14 days screening period before Day 1 of study medication dosing. Females who have received hormone replacement therapy (HRT) within 14 days prior to dosing.
  • Subjects who are positive for urine drug screening tests.
  • Subjects who have undergone major surgery within 3 months prior to Day 1.
  • Women who are pregnant or breastfeeding.
  • Subjects who received any test article within 5 half-lives or 30 days, whichever is longer, prior to Day 1 study medication dosing.
  • Subjects who previously received ABP-671.
  • Recent blood donation for more than 500 mL within 2 months of screening.
  • Subjects who consumed Seville oranges- or grapefruit-containing foods or beverages within 7 days before Day 1 and during the entire study duration.
  • Subjects with any condition that, in the judgment of the investigator, would place him/her at undue risk, or potentially compromise the results or interpretation of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single 1.0 mg dose of ABP-671 in the fasted state.

    Drug: ABP-671

  • Experimental
    Treatment B

    Single 1.0 mg dose of ABP-671 in the fed state, after a standardized breakfast.

    Drug: ABP-671

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma ABP-671 Concentration

    At times 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs.

    Time frame: 72 hours

Secondary outcomes

  1. Serum Uric Acid Concentration

    At times 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs.

    Time frame: 72 hours

  2. Serum Creatinine Concentration

    At times 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs.

    Time frame: 72 hours

  3. Urine Uric Acid Concentration

    At times 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs.

    Time frame: 72 hours

  4. Urine Creatinine Concentration

    At times 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs.

    Time frame: 72 hours

07

Study locations

1 site
  • Pharmaron CPC, Inc.
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2020, 0 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 0 months is below that.

Counting every sponsor, half of 41 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Mar 10, 2020
StartActual
May 22, 2020
Primary completionActual
Jun 9, 2020
CompletionActual
Jun 19, 2020
Last update
Jun 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04303039
Lead sponsor
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 10, 2020
Start date
May 22, 2020
Primary completion
Jun 9, 2020
Completion
Jun 19, 2020
Last update
Jun 23, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABP-671

Start the discussion